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METHODS: A 3-state Markov model was developed.
Transition probabilities, utilities, and costs were assumed.
Costs and effects were discounted at 3%. Decision analytic
CL and matrix CL were calculated as the interquartile
range (IQR) from 10,000 simulations. For each simulated
value, over or under was defined relative to the exact
value. Bias was defined as the ratio of (over  under)/
(over  under). DATA software was used for decision
analysis; S Plus was used for matrix programming.
RESULTS: Estimated life-years, quality-adjusted life-years
(QALY), and costs ($) are summarized in the table below.
CONCLUSIONS: Decision analytic software may yield bi-
ased estimates of costs and effects. The implications of this
must be considered. Analysts and policy-makers should
carefully validate all decision models prior to using them
to determine health policy.
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OBJECTIVES: A model was developed to evaluate the
cost-effectiveness of a non-nucleoside reverse transcriptase
inhibitor (RTI), delavirdine (DLV) in combination with
two nucleoside RTIs (AZT  3TC) versus a control arm
of AZT  3TC in the management of HIV/AIDS pa-
tients.
METHODS: A Markov chain model is used to describe
the clinical progression of HIV/AIDS patients based on
discrete CD4 cell count categories. The first year transi-
tion probabilities are estimated from a head-to-head clini-
cal trial comparing these regimens and subsequent annual
probabilities are derived from previously reported trials
describing the natural progression of the disease. Re-
source use and cost data are based on information col-
lected from clinical experts and include medical resource
use for routine care and the prophylaxis and treatment of
opportunistic infections. The economic and clinical effects
of antiviral treatment are examined. Sensitivity analysis
was performed to determine the robustness of the cost-
effectiveness results. The effect of time preference is in-
cluded by discounting future costs and quality-adjusted
life-years (QALYs) in the sensitivity analysis.
RESULTS: The lifetime treatment cost for a cohort of pa-
tients at beginning CD4 cell counts of 350 to 500 is
$105,880 for the DLV arm and $101,962 for the control
arm. The DLV incremental cost per QALY gained was
$13,262 for the undiscounted base case. Applying a dis-
count rate of 5% for costs alone resulted in US $12,637
per QALY gained; discounting costs and benefits at 5%
resulted in US $6854 per QALY gained.
CONCLUSIONS: The results indicate that DLV in com-
bination is a cost-effective treatment for this cohort of
patients as compared to a standard combination therapy.
Future application of the model to other treatment pat-
terns with DLV are forthcoming.
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OBJECTIVE: The study purpose was to evaluate the
overall cost of hysterectomy versus a levonorgestrel-
releasing intra-uterine device Mirena backed up by hys-
terectomy for women with heavy menstrual bleeding
(menorrhagia).
METHODS: A decision tree was based on a clinical trial
of Mirena versus hysterectomy. The model considers
pharmaceuticals, GP and specialist consultations, hyster-
ectomy, complications of surgery and surgical cancella-
tion rates. Future costs are discounted to present value at
5% per annum.
RESULTS: In the base case, over 20 years from a health-
care payer perspective, first-line treatment with Mirena is
predicted to cost $3047 versus $3800 per individual for
first-line treatment with hysterectomy. From a healthcare
funding agency (HFA) perspective, the costs are $2289
for Mirena versus $2867 for hysterectomy. From a phar-
maceuticals budget perspective, Mirena costs $639 versus
$284 for hysterectomy. In the base case, first-line treat-
ment with Mirena costs 70% to 80% of the cost of hys-
terectomy over periods of 5 to 20 years. Switching a can-
didate for hysterectomy to Mirena has the potential to
avert costs in the range $753 to $1076 per woman from
a healthcare payer perspective and $578 to $807 from an
HFA perspective. Threshold analysis shows that therapy
with Mirena will be less costly than hysterectomy pro-
vided that more than 16% of women with menorrhagia
who accept Mirena subsequently cancel hysterectomy in
Data analytic Matrix inversion
Median (IQR) Bias Median Bias
Life-years 5.187 0.086 5.186 0.068
(4.812; 5.611) (4.803; 5.605)
QALY 0.074 0.011
3.960 3.927
$ (3.669; 4.286) 0.006 (3.639; 4.251) 0.014
$ per 134,900 0.035 133,800 0.041
life-year (110,900; 160,800) (109,700; 160,000)
0.038 0.017
$ per 25,900 25,900
QALY (20,900; 31,500) (21,700; 30,300)
33,800 34,100
(27,400; 41,300) (28,200; 40,600)
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favor of continuing with Mirena. Sensitivity analyses show
that first-line therapy for menorrhagia with Mirena is
likely to be less costly than hysterectomy under all rea-
sonable scenarios for women with menorrhagia.
CONCLUSIONS: Mirena provides a cost-beneficial al-
ternative to hysterectomy for women with menorrhagia
who are candidates for hysterectomy.
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Pharmacoeconomic analysis can facilitate formulary de-
cisions to select the most optimal therapy for overactive
bladder (OAB). Budgetary decisions and disease manage-
ment programs can be implemented only when drivers of
an analysis are identified and clearly understood.
OBJECTIVE: To determine drivers of cost and effective-
ness in a cost-effectiveness analysis of OAB treatments.
METHODS: Once-daily controlled release oxybutynin-
XL (OXY-XL) was compared with conventional oxybuty-
nin immediate-release (OXY-IR) and twice daily tolterod-
ine (TOL) in a decision tree model, using the payer per-
spective. Patient outcomes included percent of patients
completely continent, with rates determined through an ef-
ficacy-analysis of literature and clinical trial data, consid-
ering randomized controlled trials and open label safety
trials. Resource utilization was based on literature and ex-
pert opinion. Costs were categorized as drug, outpatient
care, laboratory, surgery/hospitalization and other (pads).
RESULTS: The average total 6 months expected cost for
producing one continent day is lower with OXY-XL
($22) than for OXY-IR ($25) and TOL ($43) and the ex-
pected success rate is highest for OXY-XL (52%) com-
pared to OXY-IR (46%) and TOL (32%), therefore,
OXY-XL is dominant. The primary driver for the model
is percent of patients completely continent, which im-
pacts directly upon the cost of outpatient care and sur-
gery. Drug, laboratory and other are all minor compo-
nents that did not significantly impact the costs. Results
are robust against all major assumptions tested in a com-
prehensive Monte Carlo sensitivity analysis.
CONCLUSIONS: Oxybutynin-XL is more cost-effective
than immediate release oxybutynin and tolterodine in
managing OAB. The key driver in the cost-effectiveness
ratio is the superior success rate, which lowers total med-
ical costs.
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OBJECTIVE: The purpose of this study was to derive the
cost-of-care for ischemic stroke by functional status and
create a decision analytic model to compare the cost-
effectiveness of citicoline to standard therapy.
METHODS: Expert data were gathered on the average
level of resource consumption by time period (acute hos-
pital, recovery, and maintenance) and functional status
(by Barthel Index score). Resource data was gathered
from 10 experts in ischemic stroke care using a modified
Delphi panel technique. Costs were derived from na-
tional claims databases and the literature. Included in the
model were direct medical costs associated with hospital-
ization, rehabilitation, home care and medications. Effec-
tiveness was based on the utility values of the Barthel out-
comes. Clinical outcomes of treatment with citicoline and
standard care, which included the use of tPA in 3.6% of
the cases, were taken from the literature. Cost of care and
cost-effectiveness was derived using a simple linear model.
RESULTS: The cost of care for ischemic stroke patients
during the maintenance period (3–12 months) was $4274
for patients with a Barthel Index score at 3 months be-
tween 95–100, $15,981 for patients with a score between
55–90, and $35,533 for patients with a score between 0–50.
It was estimated that the expected direct medical cost per
citicoline treated ischemic stroke patient for one year is
$37,066 compared with $38,456 for standard care. The
expected utility for a patient treated with citicoline was
0.547 utilities and for standard care it was 0.479 utilities.
CONCLUSION: A change in function following ischemic
stroke drives important cost differences. The use of citi-
coline in the treatment of ischemic stroke compared to
standard care both improves outcomes and reduces cost.
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OBJECTIVE: The purpose of this study is to perform a
meta-analysis of the cost-effectiveness of tirilazad mesy-
late in the treatment of aneurysmal subarachnoid hemor-
rhage (SAH) using primary data from four multinational,
randomized, double-blind, vehicle controlled phase III
clinical trials.
METHOD: The sample was made up of those patients
who at randomization had a severe initial neurograde
(score IV or V) and received either the gender-appropri-
ate dosage or vehicle. In each of the four trials, costs were
